Mirzaiebadizi Amin, Shafabakhsh Rana, Ahmadian Mohammad Reza
Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Institute for Experimental Molecular Imaging, RWTH Aachen University Hospital, 52074 Aachen, Germany.
Biomolecules. 2025 Feb 7;15(2):242. doi: 10.3390/biom15020242.
The p21-activated kinase (PAK1), a serine/threonine protein kinase, is critical in regulating various cellular processes, including muscle contraction, neutrophil chemotaxis, neuronal polarization, and endothelial barrier function. Aberrant PAK1 activity has been implicated in the progression of several human diseases, including cancer, heart disease, and neurological disorders. Increased PAK1 expression is often associated with poor clinical prognosis, invasive tumor characteristics, and therapeutic resistance. Despite its importance, the cellular mechanisms that modulate PAK1 function remain poorly understood. Accessory proteins, essential for the precise assembly and temporal regulation of signaling pathways, offer unique advantages as therapeutic targets. Unlike core signaling components, these modulators can attenuate aberrant signaling without completely abolishing it, potentially restoring signaling to physiological levels. This review highlights PAK1 accessory proteins as promising and novel therapeutic targets, opening new horizons for disease treatment.
p21激活激酶(PAK1)是一种丝氨酸/苏氨酸蛋白激酶,在调节各种细胞过程中起关键作用,包括肌肉收缩、中性粒细胞趋化性、神经元极化和内皮屏障功能。PAK1活性异常与包括癌症、心脏病和神经疾病在内的多种人类疾病的进展有关。PAK1表达增加通常与不良临床预后、侵袭性肿瘤特征和治疗耐药性相关。尽管其很重要,但调节PAK1功能的细胞机制仍知之甚少。辅助蛋白对于信号通路的精确组装和时间调节至关重要,作为治疗靶点具有独特优势。与核心信号成分不同,这些调节剂可以在不完全消除异常信号的情况下减弱它,有可能将信号恢复到生理水平。本综述强调PAK1辅助蛋白是有前景的新型治疗靶点,为疾病治疗开辟了新视野。